Electrolyte Disturbance
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Where it strikes
Fine-tuning of Na, K, Mg, acid & water
Agents’ overall severity
Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.
Agents’ onset window
How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.
Real-world reporting for this lesion
FAERS across all lesions →How disproportionately electrolyte disturbance is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.
Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.
Documented in a profile with no reporting signal. 45 of 61 sit on a reportable term with enough reports, so FAERS could have flagged the lesion and did not; the rest are expected silences.
A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.
The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.
- NecitumumabAnti-EGFR antibody23.34 (18.19–29.94) · n=74 Reporting signal.
- PamidronateBisphosphonate · FAERS only8.00 (7.08–9.03) · n=277 Reporting signal.
- PanitumumabAnti-EGFR antibody7.65 (7.20–8.12) · n=1,157 Reporting signal.
- InfigratinibFGFR inhibitor7.41 (2.70–20.34) · n=4 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- FutibatinibFGFR inhibitor7.12 (4.21–12.02) · n=15 * Reporting signal, on terms consistent with the lesion rather than naming it.
- DinutuximabAnti-GD2 antibody · FAERS only6.98 (5.34–9.14) · n=57 Reporting signal.
- Interleukin-2 (high-dose)Cytokine6.82 (5.46–8.54) · n=82 Reporting signal.
- RetifanlimabPD-1 immune checkpoint inhibitor6.48 (3.43–12.24) · n=10 Reporting signal.
- Denileukin diftitoxImmunotoxin (IL-2–diphtheria) · FAERS only6.24 (1.95–19.92) · n=3 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- VandetanibVEGFR/EGFR/RET TKI6.21 (4.83–7.98) · n=64 * Reporting signal, on terms consistent with the lesion rather than naming it.
- ImlunestrantOral selective estrogen-receptor degrader (SERD) · FAERS only5.39 (1.98–14.67) · n=4 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- RelacorilantSelective glucocorticoid-receptor antagonist5.23 (2.13–12.85) · n=5 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- MitotaneAdrenolytic5.14 (4.17–6.35) · n=91 * Reporting signal, on terms consistent with the lesion rather than naming it.
- CisplatinPlatinum agent4.87 (4.71–5.04) · n=3,672 Reporting signal.
- TemsirolimusmTOR inhibitor4.73 (4.12–5.44) · n=207 Reporting signal.
- SelinexorXPO1 (nuclear export) inhibitor4.65 (4.20–5.14) · n=395 Reporting signal.
- CetuximabAnti-EGFR antibody4.55 (4.31–4.80) · n=1,395 Reporting signal.
- NeratinibHER2 / pan-EGFR TKI4.38 (3.58–5.36) · n=99 Reporting signal.
- CopanlisibPan-PI3K inhibitor · FAERS only4.27 (2.50–7.27) · n=14 * Reporting signal, on terms consistent with the lesion rather than naming it.
- PenpulimabPD-1 immune checkpoint inhibitor4.18 (1.54–11.37) · n=4 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- LifileucelTumor-infiltrating lymphocyte (TIL) therapy3.94 (2.16–7.21) · n=11 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Zoledronic acidBisphosphonate · FAERS only3.70 (3.54–3.87) · n=2,004 Reporting signal.
- PralatrexateAntifolate · FAERS only3.70 (2.25–6.08) · n=16 * Reporting signal, on terms consistent with the lesion rather than naming it.
- IrinotecanTopoisomerase I inhibitor · FAERS only3.69 (3.37–4.04) · n=475 Reporting signal.
- ZanubrutinibBTK inhibitor3.67 (3.10–4.35) · n=138 Reporting signal.
- EstramustineHormonal–alkylating conjugate · FAERS only3.63 (2.09–6.31) · n=13 * Reporting signal, on terms consistent with the lesion rather than naming it.
- 5-FluorouracilPyrimidine analog · FAERS only3.49 (3.36–3.63) · n=2,674 Reporting signal.
- CarboplatinPlatinum agent3.34 (3.24–3.45) · n=4,211 Reporting signal.
- NirogacestatGamma-secretase inhibitor3.30 (2.29–4.75) · n=30 * Reporting signal, on terms consistent with the lesion rather than naming it.
- MirdametinibMEK inhibitor3.27 (1.21–8.83) · n=4 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- MogamulizumabAnti-CCR4 antibody3.19 (2.41–4.22) · n=50 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Polatuzumab vedotinAntibody-drug conjugate (CD79b/MMAE)3.17 (2.84–3.55) · n=319 Reporting signal.
- SorafenibVEGFR TKI3.08 (2.85–3.34) · n=628 Reporting signal.
- EpcoritamabBispecific (CD20×CD3)3.06 (2.50–3.76) · n=95 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Tegafur-uracil (UFT)Antimetabolite (oral 5-FU prodrug)3.05 (1.36–6.86) · n=6 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- VinblastineVinca alkaloid2.99 (2.31–3.89) · n=58 Reporting signal.
- Gemtuzumab ozogamicinAntibody-drug conjugate (CD33/calicheamicin)2.98 (2.46–3.61) · n=108 Reporting signal.
- StreptozocinNitrosourea alkylator2.98 (1.32–6.69) · n=6 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- FotemustineNitrosourea (alkylating)2.94 (1.46–5.92) · n=8 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- Inotuzumab ozogamicinAntibody-drug conjugate (CD22/calicheamicin)2.84 (2.29–3.53) · n=84 Reporting signal.
- AbirateroneCYP17 inhibitor2.82 (2.66–2.99) · n=1,142 * Reporting signal, on terms consistent with the lesion rather than naming it.
- PemetrexedAntifolate2.80 (2.63–2.97) · n=1,078 Reporting signal.
- VinorelbineVinca alkaloid2.71 (2.35–3.14) · n=187 Reporting signal.
- DenosumabAnti-RANKL antibody2.69 (2.62–2.76) · n=5,326 Reporting signal.
- EtoposideTopoisomerase II inhibitor2.65 (2.53–2.77) · n=1,952 Reporting signal.
- PemigatinibFGFR inhibitor2.48 (1.61–3.82) · n=21 Reporting signal.
- IfosfamideOxazaphosphorine alkylator2.47 (2.27–2.69) · n=526 Reporting signal.
- MobocertinibEGFR exon20 TKI2.47 (1.48–4.12) · n=15 Reporting signal.
- TrabectedinMarine alkylating agent2.44 (1.88–3.18) · n=57 Reporting signal.
- TafasitamabAnti-CD19 antibody2.40 (1.82–3.15) · n=53 * Reporting signal, on terms consistent with the lesion rather than naming it.
- PentostatinPurine analog (ADA inhibitor)2.40 (1.32–4.35) · n=11 * Reporting signal, on terms consistent with the lesion rather than naming it.
- PembrolizumabPD-1 checkpoint inhibitor2.34 (2.24–2.45) · n=2,095 Reporting signal.
- AfatinibEGFR TKI2.32 (1.98–2.73) · n=153 * Reporting signal, on terms consistent with the lesion rather than naming it.
- ToripalimabPD-1 immune checkpoint inhibitor2.32 (1.68–3.21) · n=37 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Enfortumab vedotinAntibody-drug conjugate (Nectin-4/MMAE)2.29 (1.98–2.66) · n=179 Reporting signal.
- VincristineVinca alkaloid2.28 (2.11–2.46) · n=669 Reporting signal.
- IsatuximabAnti-CD38 antibody2.27 (1.91–2.69) · n=132 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Brentuximab vedotinAntibody-drug conjugate (CD30/MMAE)2.26 (1.99–2.58) · n=234 Reporting signal.
- Ibritumomab tiuxetanRadioimmunotherapy (Y-90 anti-CD20)2.24 (1.60–3.15) · n=34 * Reporting signal, on terms consistent with the lesion rather than naming it.
- CytarabineNucleoside analog2.20 (2.08–2.32) · n=1,373 Reporting signal.
- GlasdegibHedgehog (SMO) inhibitor2.12 (1.13–3.96) · n=10 * Reporting signal, on terms consistent with the lesion rather than naming it.
- BendamustineAlkylator2.11 (1.93–2.30) · n=505 Reporting signal.
- TamoxifenSERM2.10 (1.75–2.52) · n=121 Reporting signal.
- NelarabinePurine analog2.06 (1.32–3.21) · n=20 * Reporting signal, on terms consistent with the lesion rather than naming it.
- EverolimusmTOR inhibitor2.00 (1.88–2.13) · n=988 Reporting signal.
- TemozolomideAlkylator1.95 (1.77–2.15) · n=415 * Reporting signal, on terms consistent with the lesion rather than naming it.
- ObinutuzumabAnti-CD20 antibody1.95 (1.73–2.19) · n=287 Reporting signal.
- DaratumumabAnti-CD38 antibody1.92 (1.78–2.06) · n=714 Reporting signal.
- CrizotinibALK/ROS1/MET TKI1.91 (1.65–2.23) · n=171 * Reporting signal, on terms consistent with the lesion rather than naming it.
- MelphalanAlkylator1.90 (1.74–2.08) · n=480 Reporting signal.
- PirtobrutinibNon-covalent BTK inhibitor1.84 (1.10–3.06) · n=15 * Reporting signal, on terms consistent with the lesion rather than naming it.
- RibociclibCDK4/6 inhibitor1.82 (1.68–1.97) · n=594 * Reporting signal, on terms consistent with the lesion rather than naming it.
- GilteritinibFLT3 inhibitor1.80 (1.43–2.28) · n=71 Reporting signal.
- Arsenic trioxideDifferentiating agent1.78 (1.41–2.25) · n=72 Reporting signal.
- MitoxantroneAnthracenedione1.77 (1.46–2.13) · n=111 * Reporting signal, on terms consistent with the lesion rather than naming it.
- DecitabineHypomethylating agent1.74 (1.42–2.14) · n=93 Reporting signal.
- OctreotideSomatostatin analog1.73 (1.59–1.89) · n=537 Reporting signal.
- CapivasertibAKT inhibitor1.73 (1.28–2.33) · n=44 * Reporting signal, on terms consistent with the lesion rather than naming it.
- HydroxyureaRibonucleotide reductase inhibitor1.72 (1.55–1.90) · n=366 Reporting signal.
- AzacitidineHypomethylating agent1.66 (1.51–1.81) · n=499 Reporting signal.
- IdarubicinAnthracycline1.64 (1.04–2.58) · n=19 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Trastuzumab deruxtecanAntibody-drug conjugate (HER2/DXd)1.62 (1.40–1.88) · n=177 * Reporting signal, on terms consistent with the lesion rather than naming it.
- AmivantamabEGFR-MET bispecific antibody1.62 (1.25–2.10) · n=58 Reporting signal.
- RituximabAnti-CD20 antibody1.61 (1.56–1.67) · n=3,506 * Reporting signal, on terms consistent with the lesion rather than naming it.
- DabrafenibBRAF inhibitor1.56 (1.40–1.74) · n=330 * Reporting signal, on terms consistent with the lesion rather than naming it.
- VismodegibHedgehog (SMO) inhibitor1.54 (1.30–1.83) · n=138 * Reporting signal, on terms consistent with the lesion rather than naming it.
- AlpelisibPI3Kα inhibitor1.52 (1.26–1.82) · n=115 * Reporting signal, on terms consistent with the lesion rather than naming it.
- IvosidenibIDH1 inhibitor1.51 (1.07–2.13) · n=33 * Reporting signal, on terms consistent with the lesion rather than naming it.
- VenetoclaxBCL-2 inhibitor1.49 (1.40–1.59) · n=939 Reporting signal.
- VemurafenibBRAF inhibitor1.49 (1.28–1.73) · n=179 * Reporting signal, on terms consistent with the lesion rather than naming it.
- IbandronateBisphosphonate1.44 (1.24–1.67) · n=177 Reporting signal.
- GlofitamabBispecific (CD20×CD3)1.40 (1.01–1.93) · n=38 * Reporting signal, on terms consistent with the lesion rather than naming it.
- LanreotideSomatostatin analog1.37 (1.13–1.65) · n=109 * Reporting signal, on terms consistent with the lesion rather than naming it.
- FludarabinePurine analog1.36 (1.25–1.48) · n=542 Reporting signal.
- ThalidomideImmunomodulatory drug (IMiD)1.32 (1.15–1.51) · n=218 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Nimustine (ACNU)Nitrosourea (alkylating)4.09 (0.998–16.73) · n=2 No reporting signal.
- VinflunineVinca alkaloid2.28 (0.32–16.49) · n=1 No reporting signal.
- Melphalan flufenamide (melflufen)Peptide-conjugated alkylator2.06 (0.51–8.34) · n=2 No reporting signal.
- LurbinectedinMarine alkylating agent1.53 (0.92–2.55) · n=15 No reporting signal.
- ErdafitinibFGFR inhibitor1.52 (0.97–2.39) · n=19 No reporting signal.
- Obecabtagene autoleucel (Obe-cel)CD19 CAR-T cell therapy1.40 (0.20–10.10) · n=1 No reporting signal.
- Lisocabtagene maraleucelCD19 CAR-T cell therapy1.36 (0.77–2.41) · n=12 No reporting signal.
- RevumenibMenin inhibitor1.35 (0.80–2.29) · n=14 No reporting signal.
- TazemetostatEZH2 inhibitor1.29 (0.84–1.98) · n=21 No reporting signal.
- LazertinibEGFR TKI (3rd-gen)1.27 (0.70–2.29) · n=11 No reporting signal.
- Dactinomycin (actinomycin D)Antitumor antibiotic1.21 (0.83–1.77) · n=27 No reporting signal.
- Loncastuximab tesirineAntibody-drug conjugate (CD19/PBD)1.21 (0.50–2.93) · n=5 No reporting signal.
- DarolutamideAndrogen receptor inhibitor (ARSI)1.19 (0.92–1.54) · n=59 No reporting signal.
- FedratinibJAK2 inhibitor1.18 (0.72–1.93) · n=16 No reporting signal.
- MosunetuzumabBispecific (CD20×CD3)1.08 (0.61–1.90) · n=12 No reporting signal.
- InavolisibPI3Kα inhibitor1.04 (0.49–2.18) · n=7 No reporting signal.
- OsimertinibEGFR TKI1.00 (0.89–1.12) · n=282 No reporting signal.
- ImatinibBCR-ABL TKI0.89 (0.80–0.99) · n=353 No reporting signal.
- ChlorambucilAlkylating agent (nitrogen mustard)0.88 (0.63–1.23) · n=35 No reporting signal.
- EnzalutamideAndrogen-receptor inhibitor0.87 (0.80–0.95) · n=516 No reporting signal.
- NedaplatinPlatinum agent0.87 (0.43–1.74) · n=8 No reporting signal.
- PalbociclibCDK4/6 inhibitor0.73 (0.68–0.79) · n=709 No reporting signal.
- AvutometinibRAF/MEK inhibitor0.70 (0.35–1.41) · n=8 No reporting signal.
- PomalidomideImmunomodulatory drug (IMiD)0.67 (0.62–0.72) · n=702 No reporting signal.
- AmsacrineTopoisomerase II inhibitor (acridine)0.66 (0.21–2.07) · n=3 No reporting signal.
- RuxolitinibJAK1/2 inhibitor0.60 (0.54–0.65) · n=442 No reporting signal.
- Ciltacabtagene autoleucelBCMA CAR-T cell therapy0.59 (0.43–0.80) · n=39 No reporting signal.
- AvapritinibKIT / PDGFRA inhibitor0.57 (0.45–0.74) · n=61 No reporting signal.
- Idecabtagene vicleucelBCMA CAR-T cell therapy0.56 (0.27–1.17) · n=7 No reporting signal.
- DoxifluridineAntimetabolite (oral 5-FU prodrug)0.53 (0.07–3.77) · n=1 No reporting signal.
- ImetelstatTelomerase inhibitor0.53 (0.07–3.79) · n=1 No reporting signal.
- CladribinePurine analog0.51 (0.38–0.67) · n=51 No reporting signal.
- PacritinibJAK2/ACVR1 inhibitor0.42 (0.24–0.72) · n=13 No reporting signal.
- QuizartinibFLT3 inhibitor0.42 (0.14–1.31) · n=3 No reporting signal.
- SelumetinibMEK inhibitor0.35 (0.16–0.78) · n=6 No reporting signal.
- Lutetium-177 PSMA-617 (vipivotide)Radioligand therapy (PSMA)0.34 (0.26–0.45) · n=48 No reporting signal.
- OlutasidenibIDH1 inhibitor0.34 (0.05–2.43) · n=1 No reporting signal.
- TeniposidePodophyllotoxin (topo II)0.29 (0.04–2.09) · n=1 No reporting signal.
- MechlorethamineAlkylating agent (nitrogen mustard)0.22 (0.09–0.53) · n=5 No reporting signal.
- EnasidenibIDH2 inhibitor0.15 (0.06–0.35) · n=5 No reporting signal.
- MidostaurinFLT3 / multikinase inhibitor0.15 (0.05–0.47) · n=3 No reporting signal.
reporting odds ratio (log) — no signal left of the dashed line at 1.0
No ratio — no LYTE reports, or too few (count in brackets): Linvoseltamab, Telisotuzumab vedotin (Teliso-V), Zanidatamab, Ziftomenib
No ratio — under 50 FAERS reports in total: Afamitresgene autoleucel (Afami-cel), Carmofur (HCFU), Catumaxomab, Cosibelimab, Daraxonrasib, Ensartinib, Gallium nitrate, Gedatolisib, Odronextamab, Pivekimab sunirine, Plicamycin (mithramycin), Sevabertinib, Sonrotoclax, Sugemalimab, Sunvozertinib, Zenocutuzumab
No FAERS reports under the agent's name: Strontium-89 chloride
All 147 agents documented with LYTE in the atlas are shown whether or not FAERS flags them, plus the 76 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). Class composites (BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib); Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)) are not asked of FAERS; their member agents are ranked individually. 161 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR; * a signal carried by terms consistent with the lesion, not naming it. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.
At the bedside
EGFR hypomagnesemia deep dive →Anti-cancer magnesium wasting — anti-EGFR antibodies and platinums above all — is cumulative and often silent until severe. Grade a level to gauge urgency and route.
Magnesium grade & repletion
CTCAE v5.0Enter a serum magnesium level for its CTCAE grade and a directed-repletion frame. Drug-induced renal magnesium wasting (anti-EGFR antibodies, platinums) is cumulative — grade guides urgency and route.
Enter a level to see the CTCAE grade and repletion frame.
Educational aid only — not medical advice. Grades per NCI CTCAE v5.0, read directly from the column for the unit you enter. CTCAE defers to the reporting lab for the limits of normal; this tool assumes 1.7–2.6 mg/dL. Repletion route and dosing follow local protocol and clinical judgment.
Management approach
Full framework →Replace what is wasted; the drug usually continues.
Drug-level levers
- Therapy is typically continued with ongoing repletion.
- Dose-reduce or hold only for severe, symptomatic, or refractory derangements.
Pharmacologic toolkit
- Magnesium repletion — Oral and IV magnesium for anti-EGFR and cisplatin hypomagnesemia; losses are often substantial and recurrent.
- Potassium / calcium repletion — Correct coexisting hypokalemia and hypocalcemia (often magnesium-dependent).
When to biopsy
Not indicated — this is a functional tubular transport defect, not a structural lesion.
Monitoring
- · Serum magnesium, potassium, and calcium during and after therapy
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
What the guidelines say
All guidelines →Society and consensus recommendations that speak to electrolyte disturbance.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
Cited incidence across agents
Where the literature gives a representative electrolyte disturbance figure, the agents ranked highest first. Hover a dot for its cited note.
Offending agents
Signature offenders
28Agents for which electrolyte disturbance is the defining renal lesion.